Form 8-K · Current Report · Filed 2025-05-01
Cardinal Health Reports Q3 FY25 Results and Raises FY25 Guidance
Cardinal Health, Inc. reported its third-quarter fiscal year 2025 results, revealing a flat revenue of $54.9 billion. The company reported GAAP operating earnings of $730 million and non-GAAP operating earnings of $807 million, which increased by 21%. Cardinal Health also raised its fiscal year 2025 non-GAAP EPS guidance to a range of $8.05 to $8.15. A webcast will be held on May 1, 2025, to discuss these results and the outlook for the fiscal year ending June 30, 2025. The news release is furnished as Exhibit 99.1 to this report.
- Filer
- Cardinal Health Inc. CAH · NYSE
- Filed
- Accession
- 0000721371-25-000036
- CIK
- 0000721371
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$141.29
Next session
+5.8%
Since filing
+62.8%
Latest close
$230.03
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CAH reporting the same item, with the next session's move:
Exhibits (1)
About Cardinal Health Inc.
Cardinal Health Inc. is a major global healthcare services and products company, distinguished for providing end-to-end medical solutions. Specializing in healthcare distribution and supply chain management, Cardinal Health serves a comprehensive array of clients including hospitals, pharmacies, and healthcare providers. Notably, the company distributes pharmaceuticals, medical products, and laboratory supplies, ensuring efficient delivery to improve healthcare outcomes. Based in Dublin, Ohio, Cardinal Health plays a pivotal role in enhancing healthcare operational efficiency, offering extensive services like inventory management, logistics optimization, and integrated healthcare solutions that empower providers to focus on patient care. As one of the largest pharmaceutical distributors in the United States, it holds substantial influence in the healthcare sector, pivotal in ensuring the availability of drugs and medical supplies across various platforms, contributing significantly to the healthcare infrastructure worldwide.
Never miss another CAH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.